Latest ArticlesTaste masking is one of the key issues to improve drug compliance in children during the development of oral liquid preparations of traditional Chinese medicine (TCM). Because different families of TCM contain different odors, and TCMs are generally used as compound preparations in clinical practice, the taste usually presents a complex blend phenomenon. At present, the main methods to improve the taste of TCM oral liquids are medicinal materials processing, pre-treatment, preparation technology modification, adding auxiliary materials and so on. but the masking effect and application range of various masking methods are different. In practical application, the masking methods should be selected according to the drug type, dosage form and equipment needs. This paper summarizes the classification, application and new taste masking technology of TCM oral liquid preparations for children by sorting and analyzing relevant journals and patents, so as to provide reference for the research on this kind of pharmaceutical preparations.
To establish a method for determining the biological activity of adalimumab based on tumor necrosis factor-α (TNF-α) neutralization activity to provide technical means for parallel comparison of biological activities of similar biotherapeutic products of adalimumab.
The mouse fibroblast cell line L929 was used as target cell and the key reagents such as TNF-α and actinomycin D (Act-D) were standardized, then the experiment parameters including cell inoculation density, concentrations of key reagents, dilution gradient of adalimumab and incubation time were optimized. Then, the optimized method was validated by the methodology verification in the laboratory and the joint validation between laboratories to evaluate the performance of the method and its applicability to adalimumab reference products and similar biotherapeutic products.
There was a dose-response relationship between adalimumab concentrations and signal values in this method. The optimized concentrations of TNF-α and Act-D were 1 ng·mL-1 and 400 ng·mL-1 respectively, the optimized seeded cell number was 2×104 cells per well, the optimized initial antibody concentration was 1 000 ng·mL-1, the dilution ratio was 1∶2.5, and the optimized seeding time and incubation time were 18 h and 24 h. Methodological validation showed that this method was specific, reproducible and accurate. The results of joint validation were satisfactory.
This method is applicable to the five listed adalimumab products and can be used as a platform quality control method for the biological activity of adalimumab, which is convenient for the national sampling work and the parallel comparison between the products. It also provides an optional evaluation method for the establishment of national adalimumab standards and technical support for the inclusion of adalimumab monograph in Chinese Pharmacopoeia in the future.
To establish an 1H quantitative nuclear magnetic resonance (1H qNMR) method for determination of noracetildenafil.
1H qNMR spectra were obtained in CDCL3 by using Bruker Ascend 600 spectrometer with noesyigld1d pulse sequence, the relaxation delay time was 30 s, and 32 scans were recorded.
The signals δ8.15 and 9.14 of noracetildenafil and δ6.09 of 1,3,5-Trimethoxybenzene were used for quantitation. Linear regression of areas ratio (As/Ar) versus mass ratio (Ws/Wr) of δ8.15 and 6.09 yielded a correlation coefficient of 0.999 1 and regression equation of y=0.119 7x+0.003 4, the replicability RSD was 1.66% (n=5), the repeatability RSD was 0.76% (n=5), and the determined content was 97.48%. Linear regression of areas ratio (As/Ar) versus mass ratio (Ws/Wr) at δ9.14 and 6.09 yielded a correlation coefficient of 0.999 1 and regression equation of y=0.116 8x+0.004 5, the replicability RSD was 1.69% (n=5), the repeatability RSD was 0.43% (n=5), and the content of noracetildenafil was 95.35%. The result determined by 1H qNMR method (96.42%) was consistent with the results by mass balance method (96.54%) and HPLC assay method (97.07%).
The established 1H qNMR method can be used for the quantitative determination of noracetildenafil. It is accurate and rapid and could be complementary with the mass balance method for the assay of reference substances.
To analyze the pharmacokinetics of bicalutamide (50 mg) in healthy Chinese male volunteers and to evaluate the bioequivalence of domestic generic and reference bicalutamide (CASODEX®) in healthy Chinese male volunteers.
A randomized, open, two-cycle, two-sequence, and cross-over study with a 56-day washout period was conducted under fasting and postprandial conditions in healthy Chinese male volunteers (40 subjects/condition). Eligible subjects randomly received a single 50 mg dose of either the test or the reference formulation. A serial blood samples were collected over a 576-hour interval following drug administration. The concentrations of bicalutamide in EDTA-K2 human plasma were determined by the liquid chromatography-tandem mass spectrometry (LC-MS/MS) method, with non-compartmental model used for pharmacokinetic analysis. The bioequivalence of the two preparations was determined according to whether the 90% confidence interval (CI) of Cmax, AUC0-t and AUC0-∞ geometric mean ratio was within the range of 80.00%~125.00%.
The pharmacokinetic parameters of the test and reference capsules under fasting condition are as follows: Cmax (1 030±196) and (898±167) ng·mL-1; AUC0-t (224 000±42 900) and (196 000±48 400) h·ng·mL-1, AUC0-∞ (243 000±56 900) and (212 000±60 100) h·ng·mL-1. The pharmacokinetic parameters of the test and reference capsules under fed condition are as follows: Cmax (1 260±164) and (1 210±153) ng·mL-1; AUC0-t (245 000±40 700) and (241 000±44 700) h·ng·mL-1; AUC0-∞ (266 000±55 700) and (259 000±57 000) h·ng·mL-1. The 90% confidential intervals of the GMRs of Cmax, AUC0-t and AUC0-∞ fall within bioequivalence criteria (80.00%~125.00%). No serious adverse event was observed.
The domestic bicalutamide formulation is bioequivalent to the reference formulation CASODEX®. Both formulations are generally well tolerated.
To investigate the inhibitory effect and potential mechanism of Yinyanghuo (epimedii folium, EF) alcohol extract on hepatitis B virus (HBV) based on in vitro experiments and network pharmacology.
The wild-type HBV stably replicating cell line HepG 2.2.15 cells were treated with EF alcohol extract and the drug toxicity was evaluated using CCK8 assay. The HBV DNA, HBsAg and HBeAg levels were detected by PCR-fluorescent probe "one-tube method" and ELISA, and the inhibition rate was calculated. The TCMSP and GeneCards databases were used to screen the main active ingredients of EF and HBV-related targets, and the drug-active ingredient-potential disease target network was constructed with Cytoscape software. GO and KEGG enrichment analyses were performed on the core targets using the DAVID database.
The CC50 value of EF alcohol extract alone on HepG 2.2.15 cells was 1.21 mg·mL-1, and the maximum inhibition rates for HBV DNA, HBsAg and HBeAg were 59.54%, 63.07% and 45.73%, respectively (P<0.05). While the control drug tenofovir disoproxil fumarate (TDF) did not show significant inhibition for both HBsAg and HBeAg (inhibition rate <20.00%). The maximum inhibition rate of EF alcohol extract combined with TDF was 93.66% on HBV DNA, and the maximum inhibition rates on HBsAg and HBeAg were 54.97% and 61.28%, respectively (P<0.05). A total of 23 candidate active ingredients of EF and 104 potential targets for HBV treatment were screened by network pharmacology analysis. GO enrichment analysis yielded 624 entries, including 442 biological processes, 73 cellular components and 109 molecular functions; and the KEGG analysis mainly focused on signaling pathways such as cancer pathway, PI3K-Akt, lipids and atherosclerosis, human papillomavirus infection and hepatitis B.
EF can effectively inhibit the replication of wild-type HBV, and the combination of EF and TDF has a synergistic inhibitory effect, especially on antigen inhibition. EF has the characteristics of multi-component and multi-target action against HBV, which can be predicted to play roles through multiple signaling pathways. The findings provide a theoretical basis for subsequent in-depth exploration of the mechanism of EF in the treatment of HBV infection.
Simulation technology is an effective tool to improve the success rate of clinical studies, with applications at all stages of clinical research. This paper illustrated the content, requirements, and issues in three parts: simulation plan, implementation, summary, and evaluation. In the case practice of survival analysis, the article assumed a scenario where time-to-event data does not meet the proportional hazards assumption, using an exponential cure rate function model with a delayed effect. The simulation aimed to study trial design factors such as the average hazards ratio, sample size, and number of events. The results demonstrated that non-proportional hazards assumptions significantly impact the trial hypothesis, follow-up time, and analysis time. Using normal trial design methods based on the proportional hazards assumption could lead to reduced test power and unreliable interim analysis results. Simulation technology could better support the design and implementation of clinical trials. Finally, the paper discussed the importance and impact of scenario assumption in simulation implementation and execution. Also, it is pointed out that the complexity of simulation should be considered to improve the feasibility of simulation execution.
The run-in period is a specific stage after enrollment and before randomization. It is an important design element of many landmark drug clinical trials and plays an important role in drug development. However, the status quo includes non-standard design of run-in period in research protocols and inadequate reporting of run-in period in results. The author summarize the definition, type, duration, significance, advantages and disadvantages of the run-in period, and list clinical application cases, in order to provide reference for the clinical trial design and the application of the run-in period.
Depression is the most common psychological disease at present, but its pathogenesis is complex and has not been fully defined. More and more evidence shows that neuroinflammation plays an important role in the pathogenesis of depression. Nucleotide-binding oligomerization domain-like receptor protein 3 (NLRP3) is the key site of neuroinflammation. Moreover, NLRP3 inflammasome can also mediate cell apoptosis. Therefore, through reviewing the development of research on NLRP3 inflammasome, this paper explores its activation mode, composition, signal pathway regulation mechanism and related inhibitors, so as to provide new ideas and basis for the diagnosis and treatment of depression and the research and development of antidepressants.
Biopharmaceutical industry is an important part of the national economy. Drug safety is directly related to people's life and health, which is an important guarantee for social stability and economic development. In order to effectively ensure drug safety and promote the innovative development, transformation and upgrading of the biomedical industry, the national level and provincial (autonomous region, province-level municipality) governments have successively formulated and issued the "14th Five-Year Plan" for drug safety supervision and promoting high-quality development. This paper introduces the national "14th Five-Year Plan" for drug safety and promoting high-quality development at the national level. It also analyzes and compares the common measures and characteristic measures of different provinces (autonomous regions and province-level municipalities).
In recent years, with the change of people's living standards and the increasingly serious aging phenomenon, the incidence of degenerative diseases of the central nervous system is increasing. Due to the unknown etiology, such diseases seriously affect the quality of life of patients and increase the economic burden of the society and patients' families. Therefore, finding a new drug to treat this kind of disease has become a research hotspot. Procyanidins (PCs) have antioxidant, anti-apoptotic, anti-inflammatory, anticancer and neuroprotective effects, suggesting that PCs have multi-target pharmacological effects. Because of this, PCs have attracted extensive attention as natural antioxidants and have been applied in the treatment of animal models of nervous system diseases. Based on the current status of research on the pharmacological effects of PCs by domestic and foreign scholars, this paper reviews the research progress in the role and mechanism of PCs in the prevention and treatment of degenerative diseases of central nervous system and puts forward the view that PCs may be related to the inhibition of iron death in the treatment of degenerative diseases of central nervous system.
No. 86 Xueyuan South Road, Haidian District, Beijing
010-62199257
qkjq@cast.org.cn
Copyright © 2025 China Association for Science and Technology. All rights reserved. For all open access content, the relevant licensing terms apply.
Sponsored by the Office of the Leading Group for Cybersecurity and Informatization of CAST, and supported by Science and Technology Review Publishing House
